Compare Vale SA (VALE) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vale SA vs GeneDx Holdings Corp — how do they compare? Vale SA trades at $13.6 (market cap $57.32B), while GeneDx Holdings Corp trades at $67.6 (market cap $2.02B). The key difference: Vale SA is far larger — about 28.4× GeneDx Holdings Corp's market cap, and Vale SA pays a 8.87% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vale SA for 109 Days and GeneDx Holdings Corp for 19 Days on average.
| VALE | WGS | |
|---|---|---|
Market Cap | $57.32B | $2.02B |
Volume | 27,996,846 | 734,640 |
Sector | Basic Materials | Health |
52-Week High | $17.82 | $167.51 |
52-Week Low | $10.75 | $34.51 |
Typical Hold Time | 109 Days | 19 Days |
Enterprise Value | $73.56B | $2.05B |
Dividend Yield | 8.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VALE trades at $13.61, down 3.34% amid broader market weakness in steel producers. The stock shows bearish technical signals with recent earnings misses in Q4 2025 and Q1-Q2 2026. Fundamentals reveal declining revenue from $43.8B in 2022 to $38.4B in 2025, with net income margin compressing to 5.11%. Analyst consensus remains mixed with 32% buy ratings but a $16.21 price target suggesting 19% upside potential.
VALE faces headwinds from iron ore price volatility and rising operational costs, though its base metals segment shows growth potential. The current valuation at P/E 26.84 appears stretched given earnings pressure. Key risks include Brazilian regulatory exposure and cyclical commodity dependence, while the dividend yield of approximately 2.9% provides some income support.
GeneDx Holdings Corp. (WGS) trades at $68.53, down 4.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $21.02 million for 2025, though Q2 2026 earnings beat expectations. Revenue growth is positive, but profitability remains a challenge with negative margins. Analyst consensus is strongly bullish with a $81.00 price target, supported by recent product launches and institutional interest.
The outlook hinges on execution toward profitability amid high cash burn. Investment opportunity lies in the genomic testing market expansion and analyst optimism, but risks include sustained losses, competitive pressure, and reliance on financing. The stock's trajectory will depend on achieving projected margin improvements and revenue scalability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
